NCT04071262View on ClinicalTrials.gov

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

February 12, 2021

Study Completion Date

August 30, 2021

Conditions

Advanced Cancer

Interventions

DRUG

Abemaciclib

Administered orally

DRUG

Abiraterone Acetate

Administered orally

DRUG

Prednisolone

Administered orally

Trial Locations (2)

277 8577

National Cancer Center Hospital East, Kashiwa

232-0024

Yokohama City University Medical Center, Yokohama

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT04071262 - A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer | Biotech Hunter | Biotech Hunter